UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 5)*
SINOVAC BIOTECH LTD.
(Name of issuer)
Common Shares
(Title of class of securities)
P8696W104
(CUSIP number)
Andrew Y. Yan
c/o SAIF Advisors Limited
Suite 2516-2520, Two Pacific Place
88 Queensway
Hong Kong
+852 2918-2200
With a copy to:
David T. Zhang
Kirkland & Ellis
26th Floor, Gloucester Tower
The Landmark
15 Queen’s Road, Central
Hong Kong
(Name, address and telephone number of
person authorized to receive notices and communications)
January 30, 2016
(Date of event which requires filing
of this statement)
If the filing person has previously
filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are
to be sent.
* The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 2 of 7 Pages |
1 |
Names of Reporting Persons |
|
SAIF Partners IV L.P. |
2 |
Check the Appropriate Box if a Member of a Group |
(a) ¨ |
|
|
(b) x |
3 |
SEC Use Only
|
4 |
Source of Funds
WC |
5 |
Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) |
¨ |
6 |
Citizenship or Place of Organization |
|
Cayman Islands |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 |
Sole Voting Power |
|
10,780,820 |
8 |
Shared Voting Power |
|
0 |
9 |
Sole Dispositive Power |
|
10,780,820 |
10 |
Shared Dispositive Power |
|
0 |
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
10,780,820 |
12 |
Check if the Aggregate Amount In Row (11) Excludes Certain Shares |
¨ |
13 |
Percent of Class Represented By Amount In Row (11) |
|
18.9% (1) |
14 |
Type of Reporting Person |
|
PN |
(1) Based on 56,907,761 shares of Common Shares issued
and outstanding as of December 31, 2015.
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 3 of 7 Pages |
1 |
Names of Reporting Persons |
|
SAIF IV GP, L.P. |
2 |
Check the Appropriate Box if a Member of a Group |
(a) ¨ |
|
|
(b) x |
3 |
SEC Use Only
|
4 |
Source of Funds
WC |
5 |
Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) |
¨ |
6 |
Citizenship or Place of Organization |
|
Cayman Islands |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 |
Sole Voting Power |
|
10,780,820 |
8 |
Shared Voting Power |
|
0 |
9 |
Sole Dispositive Power |
|
10,780,820 |
10 |
Shared Dispositive Power |
|
0 |
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
10,780,820 |
12 |
Check if the Aggregate Amount In Row (11) Excludes Certain Shares |
¨ |
13 |
Percent of Class Represented By Amount In Row (11) |
|
18.9% (1) |
14 |
Type of Reporting Person |
|
PN |
(1) Based on 56,907,761 shares of Common Shares issued
and outstanding as of December 31, 2015.
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 4 of 7 Pages |
1 |
Names of Reporting Persons |
|
SAIF IV GP Capital Ltd. |
2 |
Check the Appropriate Box if a Member of a Group |
(a) ¨ |
|
|
(b) x |
3 |
SEC Use Only
|
4 |
Source of Funds
WC |
5 |
Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) |
¨ |
6 |
Citizenship or Place of Organization |
|
Cayman Islands |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 |
Sole Voting Power |
|
10,780,820 |
8 |
Shared Voting Power |
|
0 |
9 |
Sole Dispositive Power |
|
10,780,820 |
10 |
Shared Dispositive Power |
|
0 |
11 |
Aggregate Amount Beneficially Owned by Each Reporting Person |
|
10,780,820 |
12 |
Check if the Aggregate Amount In Row (11) Excludes Certain Shares |
¨ |
13 |
Percent of Class Represented By Amount In Row (11) |
|
18.9% (1) |
14 |
Type of Reporting Person |
|
CO |
(1) Based on 56,907,761 shares of Common Shares issued
and outstanding as of December 31, 2015.
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 5 of 7 Pages |
This Amendment No. 5 to Schedule 13D
is being filed on behalf of each of SAIF Partners IV L.P., SAIF IV GP, L.P., and SAIF IV GP Capital Ltd. (collectively, the “SAIF
Entities”), to amend the Schedule 13D filed on behalf of the SAIF entities on May 31, 2011, as amended by Amendment
No.1 to Schedule 13D filed on August 23, 2011, Amendment No.2 to Schedule 13D filed on September 30, 2011 and Amendment
No.3 to Schedule 13D filed on November 29, 2011, and Amendment No.4 to Schedule 13D filed on December 30, 2011 (the “Original
Schedule 13D”). The information in each Item below amends the information disclosed under the corresponding Item of the Original
Schedule 13D. Except as amended and supplemented in previous amendments and herein, the information
set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have
meanings as assigned thereto in the Original Schedule 13D unless defined herein. The information set forth in response to
each separate Item below shall be deemed to be a response to all Items where such information is relevant.
Item 4. Purpose of Transaction
Item 4 of the Original 13D is hereby amended
by adding the following paragraphs to the end thereof:
On January 30, 2016, Weidong Yin and SAIF
Partners IV L.P. (together with Weidong Yin, collectively, the “Buyer Group”) submitted a preliminary non-binding proposal
letter (the “Proposal Letter”) to the Issuer’s board of directors, a copy of which is attached hereto as Exhibit
7.02.
In the Proposal Letter, the Buyer Group
proposed to acquire, through an acquisition vehicle to be formed by the Buyer Group, all of the outstanding Common Shares that
are not already directly or indirectly beneficially owned by the Buyer Group for cash consideration equal to US$6.18 per Common
Share (the “Acquisition”). The Acquisition will be funded by a combination of debt and equity capital. Equity financing
will be provided by the Buyer Group in the form of cash and rollover equity in the Company. Debt financing is expected to be provided
by loans from third party financial institutions.
The Buyer Group also stated in the Proposal
Letter that that they are currently interested only in pursuing the Acquisition and are not interested in selling their shares
in any other transaction involving the Issuer. The Buyer Group expects to complete customary due diligence for the Acquisition
in a timely manner and in parallel with discussions on definitive agreements.
This Proposal Letter constitutes only a
preliminary indication of interest by the Buyer Group and does not contain all matters upon which agreement must be reached in
order to consummate the proposed Acquisition, nor does it create any binding rights or obligations in favor of any person. The
parties will be bound only upon the execution of mutually agreeable definitive documentation. If the Acquisition is completed,
Common Shares would be delisted from the NASDAQ Global Select Market, and the Issuer’s reporting obligations under the Act
would terminate.
The descriptions of the Proposal Letter
set forth above in this Item 4 do not purport to be complete and are qualified in their entirety by reference to the full text
of the Proposal Letter which has been filed as Exhibit 7.01 and is incorporated herein by this reference.
None of the Issuer or the Buyer Group is
obligated to complete the transactions described herein, and a binding commitment with respect to the Acquisition will result only
from the execution of definitive documents, and then will be on the terms provided in such documentation.
Except as indicated above, the Buyer Group
currently does not have any plans or proposals that relate to or would result in any matters listed in Items 4(a)-(j) of Schedule
13D. Consummation of the Acquisition could result in one or more of the actions specified in Items 4(a)-(j) of Schedule 13D, including
the acquisition or disposition of securities of the Issuer, a merger or other extraordinary transaction involving the Issuer, a
change to the board of directors of the Issuer to consist solely of persons to be designated by the acquisition vehicle to be formed
by the Buyer Group, and a change in the Issuer’s articles of incorporation and by-laws to reflect that the Issuer would become
a privately held company. In addition, the Buyer Group reserve their right to change his plans and intentions in connection with
any of the actions discussed in this item 4, including, among others, the purchase price and the financing arrangement for the
transactions contemplated under the Proposal Letter (including the Acquisition). Any action taken by the Buyer Group may be effected
at any time and from time to time, subject to any applicable limitations imposed by any applicable laws. No assurance can be given
that any proposal, any definitive agreement or any transaction relating to the Acquisition will be entered into or be consummated.
Item 5. Interest in Securities of the Issuer
Item
5 of the Original Schedule 13D is hereby amended and restated as follows:
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 6 of 7 Pages |
(a) Each of the SAIF Entities may be deemed
to have beneficial ownership of an aggregate of 10,780,820 Common Shares, which represents approximately 18.9% of the total Common
Shares issued and outstanding as of December 31, 2015.
(b) Each of the SAIF Entities may be deemed
to exercise sole power to vote or to direct the vote and sole power to dispose or to direct the disposition of an aggregate of
10,780,820 Common Shares.
(c) Except as otherwise described herein,
and to the knowledge of the SAIF Entities, the SAIF Entities has not affected any transaction in the Common Shares during the past
sixty (60) days.
(d) Except as otherwise described herein,
and to the knowledge of the SAIF Entities, no other person has the right to receive or the power to direct the receipt of dividends
from, or the proceeds from the sale of, the Common Shares owned by the SAIF Entities.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships
with Respect to the Securities of the Issuer
Item
6 of the Original Schedule 13D is hereby amended and restated as follows:
The Proposal Letter, which has been filed
as Exhibit 7.02 to this statement, is incorporated herein by reference in its entirety. In addition, the information set forth
in Items 3, 4 and 5 of this statement is incorporated by reference in its entirety into this Item 6. Except as otherwise described
herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the SAIF Entities and
any other person with respect to the voting or disposition of the shares of Common Shares beneficially owned by the SAIF Entities.
Item 7. Material to be Filed as Exhibits
Item
7 of the Original Schedule 13D is hereby amended and restated as follows:
Exhibit 7.01:
Joint Filing Agreement by and among SAIF Partners IV L.P., SAIF IV GP L.P. and SAIF IV GP Capital Ltd., dated as of February 2,
2016.
Exhibit 7.02:
Proposal Letter from Mr. Weidong Yin and SAIF Partners IV L.P. to the board of directors of the Issuer, dated as of January 30,
2016.
CUSIP No. P8696W104 |
SCHEDULE 13D |
Page 7 of 7 Pages |
Signature
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 2, 2016 |
SAIF Partners IV L.P. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. |
|
SAIF IV GP L.P. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P. |
|
|
|
SAIF IV GP Capital Ltd. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd. |
Exhibit 7.01
Joint Filing Agreement
In accordance with Rule 13d-1(k)(1) under
the Securities Exchange Act of 1934, as amended, each of the undersigned parties hereby agrees to file jointly the statement on
Schedule 13D (including any amendments thereto) with respect to the Common Shares, par value $0.001 per share, of Sinovac Biotech
Ltd., an Antigua company.
It is understood and agreed that each of
the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness
and accuracy of information concerning such party contained therein, but such party is not responsible for the completeness and
accuracy of information concerning another party unless such party knows or has reason to believe such information is inaccurate.
It is understood and agreed that a copy of this agreement shall be attached as an exhibit to the statement on Schedule 13D, and
any amendments thereto, filed on behalf of the parties hereto.
This Agreement may be executed in any number
of counterparts, all of which taken together shall constitute one and the same instrument.
[Remainder of this page has been left intentionally
blank.]
Signature Page
IN WITNESS WHEREOF, the undersigned hereby
execute this Agreement as of February 2, 2016.
|
SAIF Partners IV L.P. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P. |
|
|
|
|
SAIF IV GP L.P. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P. |
|
|
|
|
SAIF IV GP Capital Ltd. |
|
|
|
|
By: |
/s/ Andrew Y. Yan |
|
Name: |
Andrew Y. Yan |
|
Title: |
Director of SAIF IV GP Capital Ltd. |
Exhibit 7.02
January 30, 2016
The Board of Directors
Sinovac Biotech Ltd.
No. 39 Shangdi Xi Road,
Haidian District, Beijing 100085
People’s Republic of China
Dear Members of the Board of Directors,
The undersigned, Mr.
Weidong Yin (“Mr. Yin”), chairman, president and chief executive officer of Sinovac Biotech Ltd. (the “Company”)
and SAIF Partners IV L.P. (together with Mr. Yin, collectively, the “Buyer Group”) is pleased to submit this
preliminary non-binding proposal (the “Proposal”) to acquire all of the outstanding common shares of the Company
that are not already owned by the Buyer Group on the principal terms and conditions described in this letter (the “Transaction”).
We believe that our
Proposal provides a very attractive opportunity to the Company’s shareholders. Our Proposal represents a premium of approximately
23.11% to the closing price of the Company’s common shares on January 29, 2016, and a premium of approximately 16.62%
to the volume-weighted average closing price of the Company’s common shares during the last 90 trading days.
Set forth below are
the key terms of our Proposal.
1. Consortium. We will form
an acquisition vehicle for the purpose of implementing the Transaction. Please also note that the Buyer Group is currently interested
only in pursuing the Transaction and are not interested in selling their shares in any other transaction involving the Company.
2. Transaction and Purchase Price.
We propose to acquire all of the outstanding common shares of the Company not already owned by us at a purchase price equal to
US$6.18 per common share in cash through an acquisition vehicle newly formed by the Buyer Group with and into the Company.
3. Financing. We intend to
finance the Transaction with a combination of debt and equity capital. Equity financing will be provided by the Buyer Group in
the form of cash and rollover equity in the Company. Debt financing is expected to be provided by loans from third party financial
institutions. We are confident that we can timely secure adequate financing to consummate the Transaction.
4. Due Diligence. We believe
that we will be in a position to complete customary due diligence for the Transaction in a timely manner and in parallel with discussions
on definitive agreements.
5. Definitive Agreements.
We have engaged Kirkland & Ellis International LLP as our international legal counsel and are prepared to promptly provide
and negotiate definitive agreements for the Transaction (the “Definitive Agreements”). The Definitive Agreements
will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions
of this type.
6. Process. We believe that
the Transaction will provide superior value to the Company’s public shareholders. We recognize of course that the board of
directors of the Company will evaluate the Transaction independently before it can make its determination whether to endorse it.
Given our involvement in the Transaction, we would expect that the independent members of the board of directors will proceed to
consider our Proposal and the Transaction.
7. Confidentiality. The Buyer
Group will, as required by law, promptly file a Schedule 13D with the Securities and Exchange Commission to disclose this letter.
We are sure you will agree, however, that it is in all of our interests to ensure that we otherwise proceed in a strictly confidential
manner, unless otherwise required by law, until we have executed definitive agreements or terminated our discussions.
8. No Binding Commitment.
This Proposal is not a binding offer, agreement or agreement to make a binding offer or agreement at any point in the future. This
letter is a preliminary indication of interest by the Buyer Group and does not contain all matters upon which agreement must be
reached in order to consummate the proposed Transaction, nor does it create any binding rights or obligations in favor of any person.
The parties will be bound only upon the execution of mutually agreeable definitive documentation.
9. Governing Law. This letter
shall be governed by, and construed in accordance with, the internal laws of the State of New York.
* * * * *
In closing, we would
like to express our commitment to working together to bring this Transaction to a successful and timely conclusion. Should you
have any questions regarding this Proposal, please do not hesitate to contact us. We look forward to hearing from you.
Sincerely,
/s/ Weidong Yin
Weidong Yin
SAIF Partners IV L.P.
By SAIF Partners IV L.P., its general partner
By SAIF IV GP Capital Ltd., its general partner
/s/ Andrew Y. Yan
Name: Andrew Y. Yan
Title:
Director
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From Apr 2024 to May 2024
Sinovac Biotech (NASDAQ:SVA)
Historical Stock Chart
From May 2023 to May 2024